ENGLEWOOD, Colo., Dec. 12,
2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI)
("Zynex", "ZMS", "we" or the "Company"), an innovative medical
technology company specializing in the manufacture and sale of
noninvasive medical devices for pain management, rehabilitation,
and patient monitoring, today announced highlights from a recent
study comparing its NiCO™ laser pulse oximeter to conventional LED
pulse oximeters for the effects of skin pigmentation on SpO2
measurements conducted by the University of
California, San Francisco (UCSF) Hypoxia Lab.
Zynex's NiCO pulse oximeter utilizes highly precise laser
technology to measure blood oxygenation levels directly, as opposed
to current pulse oximeter products, which only estimate oxygenation
levels using an LED-based technology. LED pulse oximeters have been
shown to mismeasure oxygen levels in several populations, most
prominently in individuals with darker skin pigmentation.
A poster presentation for the study was recently accepted and
presented at the ANESTHESIOLOGY 2024 Event hosted by the American
Society of Anesthesiologists that took place October 18 - 22 in Philadelphia. The presentation titled,
"Laser-Based Pulse Oximetry Eliminates Effects of Skin Pigmentation
on SpO2 Measurements," included results from a study conducted
under the supervision of Dr. Philip
Bickler at the UCSF Hypoxia Lab.
Nine darkly pigmented and nine lightly pigmented participants
were recruited for this controlled desaturation study. Four NiCO
pulse oximeters and two different commercially available LED-based
pulse oximeters were used on each participant. Conclusions from the
study showed the NiCO pulse oximeter did not demonstrate a bias for
dark pigmented participants compared to lightly pigmented
participants. By comparison, conventional LED-based pulse oximeters
in the present study read falsely higher on darkly pigmented
participants, specifically at lower oxygen saturation levels.
"The findings reconfirm the results at a recent study at
Duke University that our laser-based
pulse oximeter is accurate across all pigmentation levels and is
expected to significantly reduce racial disparity in clinical
decision making, such as the need for mechanical ventilation or how
much supplemental oxygen to give a patient," said Donald Gregg, President of Zynex Monitoring
Solutions. "A 2022 study led by Harvard
Medical School researchers at Brigham and Women's Hospital
and Beth Israel Deaconess Medical Center, published in JAMA
Internal Medicine, concluded that these inaccuracies were
associated with disparities in care. The researchers found that,
compared to White patients, Black, Hispanic, and Asian patients
treated in intensive care units had greater discrepancies between
blood saturation levels detected using pulse oximeters versus
levels detected in blood samples and received less supplemental
oxygen than White patients.
"We remain confident that the clinical value of NiCO's
unparalleled precision, accuracy, and safety provides a
game-changing solution to racial disparity as we prepare our
application for FDA clearance. We look forward to additional
milestones and announcements for NiCO pulse oximetry in the weeks
to come," concluded Gregg.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and
sells medical devices used for pain management and rehabilitation
as well as non-invasive fluid, sepsis, and laser-based pulse
oximetry monitoring systems for use in hospitals. For additional
information, please visit: www.zynex.com.
Safe Harbor Statement
This release contains
forward-looking statements within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to
the future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any
of these forward-looking statements. The Company makes no express
or implied representation or warranty as to the completeness of
forward-looking statements or, in the case of projections, as to
their attainability or the accuracy and completeness of the
assumptions from which they are derived. Factors that could cause
actual results to materially differ from forward-looking statements
include, but are not limited to, the need to obtain CE marking of
new products, the acceptance of new products as well as existing
products by doctors and hospitals, larger competitors with greater
financial resources, the need to keep pace with technological
changes, our dependence on the reimbursement for our products from
health insurance companies, our dependence on third party
manufacturers to produce our products on time and to our
specifications, implementation of our sales strategy including a
strong direct sales force, the impact of COVID-19 on the global
economy and other risks described in our filings with the
Securities and Exchange Commission including but not limited to,
our Annual Report on Form 10-K for the year ended December 31,
2023 as well as our quarterly reports on Form 10-Q and current
reports on Form 8-K.
Any forward-looking statement made by us in this release is
based only on information currently available to us and speaks only
as of the date on which it is made. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Investor Relations Contact:
Brian Prenoveau, CFA
MZ Group – MZ North America
ZYXI@mzgroup.us
+561 489 5315
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zynex-ucsf-study-results-demonstrate-laser-technology-benefits-in-resolving-racial-bias-of-current-led-pulse-oximeters-302329920.html
SOURCE Zynex, Inc.